

Genzyme's diagnostics unit acquired for \$265M

Mass High Tech: The Journal of New England Technology

While rumors spread over [companies eyeing a buyout](#) [1] of Genzyme Corp. as a whole, the Cambridge biotech has indeed announced a divestiture - of its diagnostics business. Sekisui Chemical Co. Ltd. has agreed to pay \$265 million cash for Genzyme's diagnostic products business.

The acquisition will result in the diagnostics unit operating under Sekisui Medical Co. Ltd., a division of Sekisui Chemical. According to a [news release](#) [2] today, the Tokyo-based company plans to grow its global presence in its four coverage areas - medical devices, diagnostic reagents, pharmaceuticals and toxicology research.

[SOURCE](#) [3]

Source URL (retrieved on 01/29/2015 - 5:05am):

<http://www.mdtmag.com/news/2010/11/genzymes-diagnostics-unit-acquired-265m>

Links:

[1] <http://www.masshightech.com/stories/2010/11/15/daily6-Genzyme-rumor-mill-churns-over-other-suitors.html>

[2] http://www.businesswire.com/portal/site/genzyme/index.jsp?ndmViewId=news_view&ndmConfigId=1019673&newsId=20101118005839&newsLang=en

[3] <http://www.masshightech.com/stories/2010/11/15/daily42-Genzymes-diagnostics-unit-acquired-for-265M.html>